5 completed, 4 recruiting, 3 not yet recruiting, 2 unknown. 6 Not applicable, 5 Phase 2, 3 Phase 3, 2 Phase 1, 1 Early Phase 1.
Follow NAD: new trials by email Literature Review of NAD trials Research Report on NAD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEDIatric Cardiac Dysfunction Treated With Injectable Nicotinamide Adenine Dinucleotide Placebo, Nicotinamide Adenine Dinucleotide - Cardiac Dysfunction | Phase 2 | Not yet recruiting | Beijing Children's Hospital | 180 | 2026-10-01 | 2026-09-24 |
| A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults NAD+, Placebo - NAD+ Bioavailability, NAD+ Safety | Not applicable | Not yet recruiting | Reus Research | 80 | 2026-08-01 | 2026-08-11 |
| Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. Coenzyme I for Injection, NaCl (placebo) - Vascular Aging, NAD | Not applicable | Not yet recruiting | Shanghai 10th People's Hospital | 60 | 2026-01-16 | 2026-01-08 |
| NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals Nicotinamide Riboside (NR), Placebo - Sleep | Phase 2 | Recruiting | Haukeland University Hospital | 16 | 2025-10-13 | 2025-09-15 |
| Combination Gerotherapeutic Interventions for Healthspan Improvement Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging | Phase 3 | Active not recruiting | AgelessRx | 30 | 2025-07-23 | 2026-03-16 |
| A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia nicotinamide adenine dinucleotid/nicotinamide mononucleotide - Immune Thrombocytopenia, Treatment | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-15 | 2025-08-05 |
| NAD+ Oral Supplement Pilot Intervention in Adult Females Treatment, Placebo - Cognitive Change, Inflammation | Not applicable | Completed | University of Rhode Island | 53 | 2024-12-01 | 2026-03-12 |
| The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT Coenzyme I for Injection - Hematopoietic Recovery | Phase 1 | Recruiting | Anhui Provincial Hospital | 12 | 2024-11-29 | 2024-12-18 |
| Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+ Niagen®, NAD+, Placebo - Healthy Aging | Not applicable | Recruiting | Nutraceuticals Research Institute | 70 | 2024-10-31 | 2025-04-09 |
| IV Administration of ChromaDex's Niagen® as Compared to NAD+ NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral - Healthy Aging | Not applicable | Unknown | Nutraceuticals Research Institute | 53 | 2023-11-13 | 2024-04-24 |
| Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss Coenzyme I for Injection + conventional treatment, Conventional treatment - Sudden Sensorineural Hearing Loss | Early Phase 1 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 36 | 2022-02-16 | 2023-05-09 |
| Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome Naltrexone, NAD+ - Covid19, Long COVID-19 | Phase 2 | Completed | AgelessRx | 36 | 2021-01-28 | 2023-01-25 |
| A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease Nicotinamide Riboside, Placebo - Parkinson Disease | Phase 3 | Completed | Haukeland University Hospital | 410 | 2020-05-06 | 2025-09-26 |
| Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Coenzyme Q10 plus NADH, phosphoserine plus vitamin C - Chronic Fatigue Syndrome | Not applicable | Completed | Hospital Universitari Vall d'Hebron Research Institute | 282 | 2017-06-28 | 2022-09-21 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
Fatigue Syndrome, Chronic (2) · COVID-19 (1) · Fatigue (1) · Hearing Loss, Sudden (1) · Inflammation (1) · Neurodegenerative Diseases (1) · Pain (1) · Parasomnias (1) · Parkinson Disease (1) · Post-Acute COVID-19 Syndrome (1) · Primary Dysautonomias (1) · Purpura, Thrombocytopenic, Idiopathic (1)
AgelessRx (2) · Haukeland University Hospital (2) · Hospital Universitari Vall d'Hebron Research Institute (2) · Nutraceuticals Research Institute (2) · Anhui Provincial Hospital (1) · Beijing Children's Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Reus Research (1) · Shanghai 10th People's Hospital (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · University of Rhode Island (1)
China (5) · United States (5) · Norway (2) · Spain (2) · Canada (1)
Charalampos Tzoulis, MD, PhD (1) · Charalampos Tzoulis, PhD (1) · Jenell Decker, MD (1) · Jose Alegre, MD; PhD (1) · Jose Alegre-Martin, MD, PhD (1) · Katarina Lundervold, MD (1) · Lei Zhang, MD (1) · Sajad Zalzala, MD (1) · Stefanie Morgan, PhD (1) · Xiaoyu Zhu, Ph.D (1)
PMID 25386668, PMID 26212172, PMID 20447621, PMID 23514202, PMID 23600892, PMID 28052319, PMID 41035311, PMID 42056497, PMID 42063312, PMID 42848371
2025 (1), P20GM103430 (1)